Viewing StudyNCT00060684

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-05 @ 11:30 AM
Last Modification Date: 2024-10-26 @ 9:08 AM
Study NCT ID: NCT00060684
Status: COMPLETED
Last Update Posted: 2015-01-19
First Post: 2003-05-09
Brief Title: Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkins Lymphoma
Sponsor: CTI BioPharma
Organization: CTI BioPharma
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Lymphoma Small Cleaved-Cell Follicular
Lymphoma Low-Grade
Lymphoma Small Lymphocytic
Lymphoma Mixed-Cell Follicular
Keywords:
Name View
Novuspharma View
Pixantrone View
BBR 2778 View
chemotherapy View
DNA Intercalator View
mitoxantrone View
fludarabine View
dexamethasone View
Rituximab View
Rituxan View
Mabthera View
monoclonal antibody View
antibody View
NHL View
Non-Hodgkins lymphoma View
indolent View
low grade View